This refresh
Data-driven refresh July 17, 2026. The Top Picks are the Bull Rankings quality-growth screen — strong, growing businesses with durable returns at a fair price (PEG / EV-EBIT vs sector, ROIC, free cash flow). Scanned every US-listed common stock on NYSE, NASDAQ, NYSE American, and NYSE Arca (5,236 tickers); 1,453 scored on the quality-growth model (financials route to a separate card). Fundamentals from Yahoo Finance quoteSummary reconciled with as-reported SEC EDGAR filings; narrative authored by Groq (with Gemini and data-driven fallbacks).
Top Picks — quality compounders at a fair price
1. DOCS — Doximity, Inc. · score 90.5
Health Information Services · price $21.52 · 1Y $24.56 · 5Y $35.95 · 10Y $53.33
FCF $326m C · Rev +13.1% B+ · D/E 0.01 A · P/E 22.0x B+ · PEG 0.59 A-
Why now. DOCS is the unrivaled digital hub for U.S. physicians, and its AI‑powered workflow tool Ask is driving deeper engagement that fuels compounding free‑cash‑flow growth. The platform’s 30.4% profit margin and 20.6% ROE show pricing power from being the default clinical newsfeed, while 13.1% revenue growth YoY proves the network is still expanding. The thesis rests on the sticky, data‑rich ecosystem that locks clinicians in and lets Doximity monetize every clinical decision.
Moat. The moat comes from the HIPAA‑compliant AI assistant Ask and the personalized newsfeed that embed Doximity into daily clinical workflows, creating high switching costs for physicians who have built their professional identity on the platform. This lock‑in fuels the 20.6% ROE, as advertisers and pharma pay premium rates to reach a captive audience that cannot be duplicated by generic health portals.
Risk. The bear case hinges on the market’s expectation of a higher growth trajectory than the company can sustain; the reverse‑DCF implies only ~3% annual FCF growth, far below the 13.1% revenue growth, indicating the current $21.52 price already embeds heavy optimism. A slowdown to single‑digit revenue growth would crush the valuation, and a P/E of 22 is elevated for a company with a beta of 1.29, making it vulnerable to a risk‑off sell‑off. Confirmation would be a Q2 earnings miss on revenue growth or margin compression.
Horizon. 1-3 yr $24.56 (analyst consensus (n=18)) — fundamentals + valuation re-rating. 5 yr $35.95 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $53.33 if current growth sustains into durable earnings power.
2. ADBE — Adobe Inc. · score 89.8
Software - Application · price $237.25 · 1Y $272.48 · 5Y $398.93 · 10Y $591.79
FCF $10.3b A- · Rev +11.5% B · D/E 0.61 C+ · P/E 13.6x A- · PEG 0.60 A-
Why now. Adobe’s Digital Media suite – especially its Creative Cloud subscription platform – is fueling a relentless earnings engine, as evidenced by a 28.7% profit margin, a 62.8% ROE, and 11.5% FY revenue growth. The subscription model locks in recurring cash, compounding earnings at a rate that outpaces the market, and the bull case rests on the continuation of this high‑margin, high‑return subscription momentum.
Moat. The Creative Cloud ecosystem creates a deep switching cost for photographers, video editors, and designers who rely on Adobe’s integrated tools and cloud services, locking in multi‑year contracts. This stickiness, combined with Adobe’s pricing power from category leadership, drives the extraordinary 62.8% ROE, a return that competitors struggle to match without comparable platform depth.
Risk. The valuation is stretched: a P/E of 13.6 implies the market is pricing in growth that exceeds the 11.5% revenue increase, and a beta of 1.43 adds volatility risk. A slowdown in subscription renewals or aggressive pricing pressure from rivals could compress margins, and a breach of the 0.61 debt‑to‑equity threshold would amplify financial risk. The bear case is confirmed if the 10‑yr reverse‑DCF implied -2% FCF growth materializes, eroding the current upside.
Horizon. 1-3 yr $272.48 (analyst consensus (n=33)) — fundamentals + valuation re-rating. 5 yr $398.93 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $591.79 if current growth sustains into durable earnings power.
3. DLO — DLocal Limited · score 89.4
Software - Infrastructure · price $14.48 · 1Y $17.85 · 5Y $26.13 · 10Y $38.77
FCF $413m C · Rev +46.6% A · D/E 0.20 B+ · P/E 22.6x B+ · PEG 0.49 A
Why now. DLocal’s pay‑in platform for global merchants is exploding, driving 46.6% YoY revenue growth while delivering a rock‑solid 18% profit margin and 34.6% ROE. The combination of high‑margin cross‑border payments and a 22.6× P/E on that growth makes the stock a premium growth play, and the thesis hinges on the platform’s ability to keep compounding at double‑digit rates as e‑commerce and on‑demand services expand worldwide.
Moat. The moat lives in DLocal’s integrated pay‑in and pay‑out stack that supports hundreds of local APMs, creating a switching cost for merchants who need a single gateway to reach emerging markets. This network effect, paired with the company’s pricing power reflected in a 34.6% ROE, locks in recurring transaction volume that rivals can’t replicate quickly without deep local partnerships.
Risk. The biggest risk is the dilution from ongoing equity issuances, which erodes shareholder value despite the low 0.2 debt‑to‑equity ratio, and the 22.6× P/E suggests the market may already be pricing in aggressive growth. A slowdown in cross‑border e‑commerce or a failure to curb dilution would push the multiple lower and break the upside.
Horizon. 1-3 yr $17.85 (analyst consensus (n=10)) — fundamentals + valuation re-rating. 5 yr $26.13 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $38.77 if current growth sustains into durable earnings power.
4. NBIX — Neurocrine Biosciences, Inc. · score 87.6
Drug Manufacturers - Specialty & Generic · price $170.88 · 1Y $199.27 · 5Y $291.76 · 10Y $432.80
FCF $831m C+ · Rev +28.6% A- · D/E 0.14 B+ · P/E 26.3x B · PEG 0.49 A
Why now. Neurocrine’s blockbuster INGREZZA, now expanding into Huntington’s disease, is fueling a 28.6% YoY revenue surge while the business delivers a 21.6% profit margin and trades at a razor‑thin PEG of 0.49, meaning the market is undervaluing a high‑growth, high‑margin franchise. The compounding engine is the expanding indication set for INGREZZA plus the pipeline of Orilissa and Oriahnn, which should keep revenue growth above 20% for years. The thesis hinges on sustaining that double‑digit growth as the drug portfolio deepens its market penetration.
Moat. INGREZZA’s FDA‑approved indication for tardive dyskinesia and Huntington’s disease creates a high‑entry barrier—patients and neurologists rarely switch once a tolerable regimen is found, cementing long‑term demand. Neurocrine’s 19.6% ROE stems from pricing power in these niche endocrine and neurological markets, where few competitors can match the clinical data and specialty‑care distribution network. The company’s patented formulations and limited‑competition pipelines lock in cash flow and protect margins.
Risk. The stock trades at a premium P/E of 26.3 despite a modest market cap of $17.2 B, implying the market has already priced in aggressive growth; any slowdown in the 28.6% revenue trajectory or a setback in the pipeline would force a re‑rating. Additionally, the business is heavily concentrated on a handful of products—any regulatory or safety issue could erode the 21.6% margin quickly. A miss on next‑quarter sales or a negative trial outcome would trigger a sell‑off, confirming the bear case.
Horizon. 1-3 yr $199.27 (analyst consensus (n=28)) — fundamentals + valuation re-rating. 5 yr $291.76 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $432.80 if current growth sustains into durable earnings power.
5. PCTY — Paylocity Holding Corporation · score 86.9
Software - Application · price $126.00 · 1Y $152.95 · 5Y $223.93 · 10Y $332.19
FCF $487m C · Rev +12.5% B+ · D/E 0.11 B+ · P/E 26.9x B+ · PEG 0.97 B+
Why now. Paylocity’s integrated talent‑management suite—recruiting, onboarding and performance tools—locks mid‑market employers into a single cloud platform, fueling a durable revenue compounder. The business is growing 12.5% YoY, generating $487 m of free cash flow and delivering a high ROE of 21.9%, all at a modest PEG of 0.97. The thesis rests on the continued expansion of its HR‑to‑payroll ecosystem, which compounds earnings as more customers add modules.
Moat. The end‑to‑end HCM cloud stack creates switching costs that rival a payroll‑only provider; once a client adopts Paylocity’s payroll, HR, time‑and‑attendance and talent modules, migration costs skyrocket. This lock‑in, combined with a 21.9% ROE driven by pricing power in the U.S. mid‑market payroll space, gives Paylocity a defensible edge that competitors can’t replicate quickly.
Risk. The stock trades at a forward P/E of 26.9, far above many software peers, and the Bull Rankings reverse‑DCF implies a -9% annual free‑cash‑flow growth rate baked into today’s $126 price. If revenue growth stalls below the current 12.5% pace or margins compress, the premium valuation collapses. A sustained slowdown in new‑module adoption would trigger the bear case.
Horizon. 1-3 yr $152.95 (analyst consensus (n=19)) — fundamentals + valuation re-rating. 5 yr $223.93 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $332.19 if current growth sustains into durable earnings power.
6. EXLS — ExlService Holdings, Inc. · score 85.9
Information Technology Services · price $28.16 · 1Y $40.13 · 5Y $58.75 · 10Y $87.15
FCF $297m C · Rev +13.4% B+ · D/E 0.67 C+ · P/E 17.9x A- · PEG 0.88 B+
Why now. EXLS is poised to dominate AI‑driven claims and underwriting automation for insurers, a segment where its digital operations platform is already entrenched. The business is scaling at 13.4% YoY revenue growth while delivering a 11.7% profit margin and a stellar ROE of 32.3%, all on a modest PE of 17.9x—a rare blend for a high‑growth tech services firm. The thesis rests on the relentless compounding of AI‑enabled services across Insurance, Healthcare and Banking, which should keep the growth engine humming for years.
Moat. EXLS’s moat lives in its end‑to‑end AI platform that handles claims management, policy servicing and actuarial analytics for large insurers, creating deep data integration and switching costs. The high ROE stems from pricing power in these high‑margin, data‑intensive contracts, where clients cannot easily replace the embedded analytics without disrupting operations. This entrenched footprint across multiple regulated industries shields the business from new entrants.
Risk. The biggest headwind is the concentration in the insurance AI market, where a slowdown in underwriting activity or a shift to in‑house solutions could compress margins; the current PE of 17.9x, while reasonable, already prices in continued double‑digit growth. A dip in revenue growth below the 13% historical rate would force the valuation to re‑price, and a rise in debt‑to‑equity above 0.67 could strain balance‑sheet flexibility. A sustained margin contraction below the current 11.7% would confirm the bear case.
Horizon. 1-3 yr $40.13 (analyst consensus (n=8)) — fundamentals + valuation re-rating. 5 yr $58.75 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $87.15 if current growth sustains into durable earnings power.
7. NVDA — NVIDIA Corporation · score 85.8
Semiconductors · price $202.81 · 1Y $301.97 · 5Y $442.11 · 10Y $655.84
FCF $119.1b A · Rev +70.7% A · D/E 0.07 A- · P/E 31.1x B · PEG 0.65 A-
Why now. NVIDIA’s AI‑driven Compute & Networking platform is exploding, with data‑center revenue surging 70.7% YoY and profit margins soaring to 63%, delivering an ROE of 81.7%—the highest in semis. This compounding cash‑flow engine, powered by GeForce and RTX GPUs that dominate gaming and enterprise workloads, will keep free cash flow expanding at the 48% annual rate our reverse‑DCF assumes, making the current price a premium bet on relentless AI adoption. The thesis hinges on the continued capture of AI infrastructure spend across cloud, enterprise, and automotive customers.
Moat. NVIDIA’s moat lies in its proprietary GPU architecture and CUDA software ecosystem that lock in hyperscale cloud providers, enterprise AI labs, and automotive OEMs, creating massive switching costs. The Compute & Networking segment’s AI accelerators command pricing power, reflected in an 81.7% ROE, because no competitor can match the integration of hardware and software at scale. This entrenched position in the data‑center and automotive AI stack shields margins from commoditization.
Risk. The bear case centers on the lofty valuation: a forward P/E of 31.1 implies the market already expects sustained double‑digit growth, yet any slowdown in AI spend or a successful challenger in GPU design could compress margins and drive the stock toward its 52‑week low of $164.07. A spike in beta‑driven volatility (beta 2.21) would amplify downside on broader market stress. Confirmation would be a miss on revenue growth or a margin dip below 60%, triggering a re‑rating to “sell.”
Horizon. 1-3 yr $301.97 (analyst consensus (n=58)) — fundamentals + valuation re-rating. 5 yr $442.11 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $655.84 if current growth sustains into durable earnings power.
8. ADMA — ADMA Biologics, Inc. · score 84.6
Biotechnology · price $8.71 · 1Y $17.00 · 5Y $24.89 · 10Y $36.92
FCF $108m C · Rev +11.0% B · D/E 1.11 C · P/E 12.8x A · PEG 0.65 A-
Why now. ADMA’s IVIG franchise (BIVIGAM and ASCENIV) is set to compound earnings as U.S. immune‑deficiency demand expands, delivering 11% revenue growth YoY while the business converts that into a 42.4% ROE and trades at a razor‑thin PEG of 0.65—a clear mispricing signal. The combination of high margin (32.4%) and a $108 M free‑cash‑flow runway fuels share‑buybacks that will amplify EPS, making the upside hinge on sustained IVIG uptake.
Moat. ADMA controls the entire plasma‑to‑product pipeline through its ADMA BioManufacturing and Plasma Collection Centers, creating a cost‑advantage and supply‑security moat that few competitors can replicate quickly. This vertical integration underpins pricing power in the IVIG market, driving the extraordinary 42.4% ROE and protecting margins against generic pressure.
Risk. The stock is already priced near its 52‑week high of $20.46 and the Bull Rankings model’s reverse DCF shows only ~3% annual free‑cash‑flow growth baked into today’s $8.71 price—far below the 11% revenue growth trajectory, implying optimism that could evaporate if growth stalls or the debt‑to‑equity of 1.11 limits further buybacks. A slowdown in IVIG adoption or a margin squeeze would trigger a re‑rating toward the lower end of the analyst range.
Horizon. 1-3 yr $17.00 (analyst consensus (n=5)) — fundamentals + valuation re-rating. 5 yr $24.89 at ~23% CAGR — compounding case rests on the competitive position widening. 10 yr $36.92 if current growth sustains into durable earnings power.
9. ANIP — ANI Pharmaceuticals, Inc. · score 84.1
Drug Manufacturers - Specialty & Generic · price $79.20 · 1Y $112.71 · 5Y $165.02 · 10Y $244.80
FCF $191m C · Rev +37.0% A · D/E 1.12 C · P/E 20.3x B+ · PEG 0.46 A
Why now. ANI’s eye‑care franchise – ILUVIEN and YUTIQ – is scaling rapidly across specialty pharmacies and hospital networks, fueling a 37% YoY revenue surge that outpaces peers. The market still values the stock at a modest PEG of 0.46 despite a PE of 20.3, indicating ample upside as growth compounds. The thesis rests on sustaining this ophthalmic compounding, which the company’s 16.3% ROE and $191 m free‑cash‑flow generation prove it can fund.
Moat. ANI’s durable edge lies in its integrated injectable and softgel manufacturing platform that supplies high‑margin ocular products directly to specialty pharmacies, retail chains, and hospitals – a distribution web that rivals cannot replicate quickly. Pricing power in the ILUVIEN/YUTIQ segment drives the 16.3% ROE, while the controlled‑substance and potent‑product capabilities create switching costs for customers seeking reliable, compliant supply.
Risk. The stock trades at a premium PE of 20.3 while the Bull Rankings model’s reverse DCF assumes a negative 8% annual free‑cash‑flow growth, meaning any slowdown in the 37% revenue growth or margin compression would expose overvaluation. A debt‑to‑equity of 1.12 adds leverage risk if cash generation falters. A breach of the 20% revenue growth threshold would trigger a sharp re‑rating and validate the bear case.
Horizon. 1-3 yr $112.71 (analyst consensus (n=7)) — fundamentals + valuation re-rating. 5 yr $165.02 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $244.80 if current growth sustains into durable earnings power.
10. CARG — CarGurus, Inc. · score 83.7
Auto & Truck Dealerships · price $35.00 · 1Y $37.38 · 5Y $54.73 · 10Y $81.20
FCF $293m C · Rev +14.0% B+ · D/E 0.79 B · P/E 18.4x B · PEG 1.03 B+
Why now. CarGurus’ Digital Deal platform is turning its massive shopper audience into a high‑margin, recurring revenue engine, and that engine is accelerating. The business is growing revenue at 14% YoY while delivering a 15.9% profit margin and a staggering 62.9% ROE, proving it can reinvest earnings into growth without diluting returns. With the stock trading at a modest PE of 18.4x and the analyst consensus 1‑yr target already 7% above the $35 price, the compounding power of Digital Deal and dealer subscriptions makes the upside virtually locked in.
Moat. The moat lies in CarGurus’ integrated marketplace that couples a large, engaged buyer base with a deep dealer network, creating a two‑sided network effect that rivals can’t replicate quickly. Dealer subscription fees and advertising lock dealers into the platform, while the Digital Deal workflow embeds CarGurus into the purchase journey, raising switching costs for both shoppers and dealers. This virtuous loop fuels the 62.9% ROE, reflecting pricing power from category leadership in online auto retail.
Risk. The biggest headwind is valuation optimism: a PE of 18.4x is above the sector average and the Bull Rankings model’s reverse‑DCF implies a -1% annual free‑cash‑flow growth rate, meaning the market is already pricing in aggressive future cash generation. Any slowdown in revenue growth or margin compression would expose that over‑valuation, and a rise in debt‑to‑equity above the current 0.79 could amplify the downside. A breach of the 52‑week low ($26.39) would confirm the bear case.
Horizon. 1-3 yr $37.38 (analyst consensus (n=13)) — fundamentals + valuation re-rating. 5 yr $54.73 at ~9% CAGR — compounding case rests on the competitive position widening. 10 yr $81.20 if current growth sustains into durable earnings power.
11. EPAM — EPAM Systems, Inc. · score 83.2
Information Technology Services · price $88.66 · 1Y $135.94 · 5Y $199.03 · 10Y $295.25
FCF $544m C+ · Rev +14.2% B+ · D/E 0.08 B+ · P/E 12.7x A · PEG 0.44 A
Why now. EPAM’s digital platform engineering and cloud services are the engine of enterprise transformation, and that engine is revving at a 14.2% revenue growth rate while generating $544 m of free cash flow and trading at a rock‑bottom PE of 12.7×. Those fundamentals give the company a runway to compound earnings through sticky, high‑margin engineering contracts and a disciplined buy‑back program that will amplify EPS. The whole thesis rests on the persistence of that recurring‑services compounding engine.
Moat. EPAM’s moat lives in its end‑to‑end engineering platform that couples requirements analysis, cloud migration, AI‑driven analytics, and smart‑automation into a single delivery model. Large enterprises face massive switching costs because re‑architecting core applications across multiple clouds would require rebuilding the very platform EPAM has already embedded, giving EPAM pricing power and a defensible revenue base.
Risk. The bull case hinges on continued high‑growth contracts, but the Bull Rankings model flags a reverse‑DCF implied free‑cash‑flow growth of –3% / yr, far below the 14.2% revenue expansion, suggesting the market is already pricing in a sharp slowdown. Add a beta of 1.43 and a modest ROE of 11.3%, and any earnings miss could trigger a sell‑off. A sustained dip in margin or a failure to execute buy‑backs would confirm the bear view.
Horizon. 1-3 yr $135.94 (analyst consensus (n=17)) — fundamentals + valuation re-rating. 5 yr $199.03 at ~18% CAGR — compounding case rests on the competitive position widening. 10 yr $295.25 if current growth sustains into durable earnings power.
12. RMD — ResMed Inc. · score 83.2
Medical Instruments & Supplies · price $198.99 · 1Y $252.20 · 5Y $369.25 · 10Y $547.75
FCF $1.8b C+ · Rev +10.3% B · D/E 0.13 B+ · P/E 19.2x A- · PEG 1.13 B+
Why now. ResMed’s cloud‑connected sleep‑diagnostic platform – anchored by the NightOwl disposable device and the ApneaLink Air portable recorder – is locking in recurring software fees that let the business compound at a secular pace; revenue is already expanding 10.3% YoY, profit margins sit at a healthy 27.4%, and free cash flow tops $1.8 B on a $28.9 B market cap, delivering a 6.2% FCF yield. The compounding engine is the growing adoption of home‑based sleep testing across hospitals and clinics, and the thesis rests on that stick‑fast pipeline of device‑software revenue staying ahead of modest macro‑headwinds.
Moat. ResMed’s moat is the tightly integrated hardware‑plus‑cloud software stack that ties hospitals, sleep clinics and home users to its proprietary data platform; switching to a competitor means replacing both the diagnostic device and the SaaS analytics, a costly transition. This lock‑in fuels a ROE of 23.4%, reflecting pricing power from being the category leader in cloud‑enabled respiratory health and the low‑cost, high‑margin nature of its software recurring revenue.
Risk. The market is pricing in growth that outstrips fundamentals – a forward P/E of 19.2 for a company growing revenue only 10.3% and a reverse‑DCF that assumes a mere 1% annual free‑cash‑flow expansion for the next decade. Any slowdown in device adoption or a shift to lower‑margin generic alternatives would compress margins and invalidate the optimistic valuation, and a breach of the 0.13 debt‑to‑equity ceiling would further erode confidence. A sustained miss on the 10‑year FCF growth assumption would trigger a sharp re‑rating.
Horizon. 1-3 yr $252.20 (analyst consensus (n=15)) — fundamentals + valuation re-rating. 5 yr $369.25 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $547.75 if current growth sustains into durable earnings power.
13. VEEV — Veeva Systems Inc. · score 82.4
Health Information Services · price $195.38 · 1Y $244.59 · 5Y $358.11 · 10Y $531.23
FCF $1.7b C+ · Rev +16.2% B+ · D/E 0.01 A- · P/E 34.6x C+ · PEG 0.87 B+
Why now. Veeva’s Vault CRM Suite is cementing its position as the de‑facto operating system for pharma sales teams, driving a 16.2% YoY revenue growth while delivering a 28.4% profit margin and a $1.7B free‑cash‑flow generation base. That operating leverage, combined with a low debt‑to‑equity of 0.01, lets the business compound cash at double‑digit rates, and the 8% FCF growth implied by our reverse‑DCF is already baked into the price – the upside rests on sustaining the high‑growth Vault platform across its global customer base.
Moat. The Vault ecosystem locks in large pharmaceutical and biotech clients through deep integration of CRM, content management (PromoMats) and analytics (Crossix), creating switching costs that rival core ERP systems. Veeva’s OpenData and Link layers enrich the platform with proprietary reference data, giving customers a single source of truth that competitors cannot replicate without massive data acquisition and integration effort.
Risk. The 34.6× forward P/E suggests the market is pricing in continued premium growth; any slowdown in Vault adoption or a pricing pressure from emerging low‑cost cloud rivals would compress margins and erode the 28.4% profit margin. A breach of the current 0.01 debt‑to‑equity ratio or a beta near 1 could amplify downside, and a sustained revenue growth dip below the 16% YoY rate would validate the bearish view that the current valuation is overly optimistic.
Horizon. 1-3 yr $244.59 (analyst consensus (n=27)) — fundamentals + valuation re-rating. 5 yr $358.11 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $531.23 if current growth sustains into durable earnings power.
14. ACN — Accenture plc · score 82.1
Information Technology Services · price $143.57 · 1Y $179.13 · 5Y $262.27 · 10Y $389.05
FCF $12.6b A- · Rev +6.7% C+ · D/E 0.25 B · P/E 11.5x A · PEG 0.98 B+
Why now. Accenture’s relentless expansion of its intelligent platform and cloud services for Fortune‑500 enterprises is driving a compounding engine, underpinned by 6.7% revenue growth YoY, a rock‑solid PE of 11.5 that signals deep discount to peers, and a stellar ROE of 24.4% that reflects pricing power in high‑margin consulting. The thesis hinges on the continued shift of global corporates toward AI‑enabled digital transformation, which fuels repeatable, high‑margin contracts and sustains growth.
Moat. The moat lives in Accenture’s end‑to‑end delivery model—its integrated suite of strategy, systems integration, AI, and managed services creates multi‑year, lock‑in contracts that are costly for rivals to replicate. The firm’s deep relationships with large enterprises across finance, insurance, and health services generate switching costs and economies of scale that protect its 24%+ ROE.
Risk. The bear case centers on the modest growth profile; a 6.7% revenue increase is below the sector’s high‑growth peers, and a P/E of 11.5, while low, may already price in aggressive cost‑cutting. If macro‑economic headwinds curb corporate IT spend, the 0.25 debt‑to‑equity ratio could rise, squeezing margins. A sustained slowdown in top‑line growth would validate the Bull Rankings model’s weakest pillar—Growth—and could push the stock back toward its 52‑week low of $118.15.
Horizon. 1-3 yr $179.13 (analyst consensus (n=25)) — fundamentals + valuation re-rating. 5 yr $262.27 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $389.05 if current growth sustains into durable earnings power.
15. DXCM — DexCom, Inc. · score 80.9
Medical Devices · price $76.65 · 1Y $85.46 · 5Y $125.12 · 10Y $185.61
FCF $1.4b C+ · Rev +16.1% B+ · D/E 0.47 B · P/E 32.9x C+ · PEG 1.38 B
Why now. DexCom’s G7 platform is cementing its lead in the U.S. CGM market, driving a 16.1% YoY revenue growth while delivering a 19.3% profit margin that fuels a 31.5% ROE; this high‑margin growth engine will keep compounding earnings as diabetes prevalence expands.
Moat. The integrated Dexcom G7 + Share ecosystem locks patients and endocrinologists into a data‑rich platform that is costly to replace, while patented sensor technology and FDA clearance create a barrier to entry; the resulting pricing power underpins the 31.5% ROE, far above peers.
Risk. The stock trades at a lofty PE of 32.9 and a beta of 1.45, implying a reverse‑DCF 20% FCF growth rate that outpaces the actual 16.1% revenue growth, so any slowdown or pricing pressure would crush valuation multiples. A breach of the 52‑week low would confirm the over‑optimism.
Horizon. 1-3 yr $85.46 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $125.12 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $185.61 if current growth sustains into durable earnings power.
16. CVSA — Covista Inc. · score 80.4
Education & Training Services · price $118.00 · 1Y $156.25 · 5Y $228.77 · 10Y $339.36
FCF $336m C · Rev +9.7% B · D/E 0.54 B+ · P/E 17.2x B+ · PEG 0.88 B+
Why now. Covista’s Chamberlain University is scaling its online nursing and health‑professionals pipeline, driving a 9.7% FY revenue growth while delivering a solid 12.3% profit margin and a healthy free cash flow of $336 m. The combination of a low‑beta (0.62) and a modest debt‑to‑equity of 0.54 lets the company reinvest earnings into expanding its accredited degree programs, compounding earnings at a sustainable pace. The thesis hinges on continued enrollment growth in its high‑margin medical and veterinary segments, which fuels the next wave of cash‑flow expansion.
Moat. Covista’s moat lives in its vertically integrated university system—Chamberlain, Walden, and the Medical & Veterinary schools—each holding federal accreditation and deep relationships with hospitals and licensing boards. This creates high switching costs for students and employers, while the university’s proprietary online platform locks in tuition revenue and protects margins, enabling the company to out‑pace peers in cost‑efficient delivery.
Risk. The bear case centers on the price premium baked into the stock: a forward P/E of 17.2 sits above the sector median, and the Bull Rankings model’s reverse DCF implies a -10% annual free‑cash‑flow growth rate, far below the 9.7% revenue growth. A slowdown in enrollment or tighter federal funding could compress margins, and a breach of the 0.54 debt‑to‑equity ceiling would force costly refinancing. Confirmation would be a quarterly earnings miss that pushes the P/E above 20 and triggers a sell‑off.
Horizon. 1-3 yr $156.25 (analyst consensus (n=4)) — fundamentals + valuation re-rating. 5 yr $228.77 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $339.36 if current growth sustains into durable earnings power.
17. APP — AppLovin Corporation · score 80.3
Advertising Agencies · price $424.54 · 1Y $654.60 · 5Y $958.40 · 10Y $1,422
FCF $4.4b B · Rev +66.4% A · D/E 1.63 C · P/E 36.9x C+ · PEG 1.23 B
Why now. AppLovin’s AI‑driven MAX in‑app bidding platform is the growth engine that will keep revenue compounding at a blistering pace, as evidenced by 66.4% YoY revenue growth and a 64.3% profit margin that translates into $4.4B of free cash flow. The market is already pricing in a 40% annual FCF expansion, but the real driver is the scalable auction network that captures ever‑larger ad spend, making the upside hinge on sustaining this AI‑powered compounding.
Moat. MAX creates a real‑time competitive auction that locks publishers into a high‑margin ecosystem; once integrated, switching costs soar because developers rely on the same data and optimization loop that fuels higher CPMs. Coupled with Adjust’s analytics lock‑in, AppLovin commands a sticky, data‑rich stack that rivals cannot replicate quickly.
Risk. The stock trades at a lofty PE of 36.9 and a beta of 2.48, reflecting market expectations that may be overstated; a slowdown from the current 66.4% revenue growth or margin compression would invalidate the 40% FCF growth assumption and trigger a sharp re‑rating. A rise in debt‑to‑equity to 1.63 further amplifies downside if cash flow falters.
Horizon. 1-3 yr $654.60 (analyst consensus (n=30)) — fundamentals + valuation re-rating. 5 yr $958.40 at ~18% CAGR — compounding case rests on the competitive position widening. 10 yr $1,422 if current growth sustains into durable earnings power.
18. PRDO — Perdoceo Education Corporation · score 80.2
Education & Training Services · price $31.66 · 1Y $36.41 · 5Y $53.31 · 10Y $79.08
FCF $225m C · Rev +17.7% B+ · D/E 0.12 A- · P/E 12.1x A- · PEG 0.78 A-
Why now. Perdoceo’s AIUS and CTU segments are riding a secular surge in career‑oriented online education, delivering 17.7% YoY revenue growth, 19.9% profit margin and a modest PE of 12.1, which together fuel a compounding earnings engine that can sustain double‑digit returns as enrollment expands and margins improve.
Moat. The university‑wide accreditation and credit‑transfer framework create high switching costs for students, while the focus on high‑demand fields such as nursing, cybersecurity and healthcare management lets PRDO command pricing power, reflected in a solid 17% ROE driven by these niche program advantages.
Risk. The Bull Rankings model flags a reverse‑DCF implied free‑cash‑flow contraction of –15% annually, suggesting the market is pricing in aggressive cash‑flow growth that may be unrealistic if enrollment slows or margins compress, and a near‑term earnings dip would shatter the upside narrative.
Horizon. 1-3 yr $36.41 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $53.31 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $79.08 if current growth sustains into durable earnings power.
19. META — Meta Platforms, Inc. · score 79.5
Internet Content & Information · price $646.01 · 1Y $826.63 · 5Y $1,210 · 10Y $1,795
FCF $48.3b A · Rev +26.2% A- · D/E 0.36 B+ · P/E 23.5x B · PEG 0.96 B+
Why now. Meta’s Family of Apps is cementing a compounding engine by leveraging AI‑enhanced Reels and Marketplace, driving revenue up 26.2% YoY while preserving a 32.8% profit margin and generating $48.3B of free cash flow. The combination of a 29% ROE and a strong‑buy consensus pushes the stock toward a multi‑year upside, and the thesis hinges on the FoA segment’s ability to keep monetizing its massive user network at these high margins.
Moat. The Facebook‑Instagram ecosystem creates a lock‑in network effect: billions of daily active users feed data into a self‑reinforcing ad platform that competitors cannot replicate quickly. This scale fuels a pricing advantage that translates into the 29% ROE, as advertisers pay premium CPMs to reach a captive audience across feed, reels, and stories.
Risk. The market is pricing in a reverse‑DCF implied free‑cash‑flow growth of ~30% per year, far above the reported 26.2% revenue growth, meaning the current P/E of 23.5 is stretched; any slowdown in ad spend or a dip in margin would expose the overvaluation. A bear trigger would be a margin contraction below 30% or a sustained earnings miss that forces the P/E toward the sector average, eroding the upside.
Horizon. 1-3 yr $826.63 (analyst consensus (n=58)) — fundamentals + valuation re-rating. 5 yr $1,210 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $1,795 if current growth sustains into durable earnings power.
20. PODD — Insulet Corporation · score 79.4
Medical Devices · price $164.06 · 1Y $238.22 · 5Y $348.77 · 10Y $517.38
FCF $416m C · Rev +31.9% A · D/E 0.78 C+ · P/E 38.4x C+ · PEG 1.40 B
Why now. The Omnipod 5 automated insulin delivery system is unlocking a new wave of adoption, propelling revenue at a 31.9% YoY pace while delivering a healthy 10.4% profit margin and generating $416 m of free cash flow—a rare cash‑rich growth engine in med‑tech. With a PEG of 1.4 and a 23.2% ROE, the business compounds earnings faster than peers, and the upside hinges on scaling the Omnipod platform globally.
Moat. Insulet’s Omnipod line embeds a proprietary AID algorithm and Bluetooth‑enabled pod that lock patients into a seamless, wireless workflow, creating high switching costs for diabetics accustomed to the system. This technology advantage fuels pricing power, reflected in a 23.2% ROE, and the integrated hardware‑software stack is difficult for rivals to replicate quickly.
Risk. The stock trades at a lofty PE of 38.4, implying that the market already assumes a sustained 21% free‑cash‑flow growth—well above the sector norm and vulnerable to any slowdown in the 31.9% revenue surge. A debt‑to‑equity of 0.78 adds leverage risk, and a beta of 1.11 amplifies downside in a market pullback. A miss on Omnipod adoption or margin compression would validate the over‑optimistic valuation.
Horizon. 1-3 yr $238.22 (analyst consensus (n=23)) — fundamentals + valuation re-rating. 5 yr $348.77 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $517.38 if current growth sustains into durable earnings power.
21. MELI — MercadoLibre, Inc. · score 79.2
Internet Retail · price $1813.91 · 1Y $2,215 · 5Y $3,243 · 10Y $4,810
FCF $11.8b A- · Rev +36.4% A · D/E 1.70 C+ · P/E 47.9x C · PEG 1.16 B+
Why now. MercadoLibre’s unstoppable compounding comes from its integrated Mercado Pago ecosystem, which fuels a 36.4% YoY revenue growth and generates a massive $11.8 B free cash flow run-rate, while the business still trades at a lofty PE of 47.9—a premium justified only by the relentless expansion of its payments and logistics arms. The thesis rests on the fact that each new Marketplace transaction deepens the payments moat, creating a virtuous cycle that will keep cash and earnings accelerating.
Moat. The moat lives in the network effect of Mercado Pago linked to the Marketplace: merchants and consumers are locked into a single‑stop shop for buying, paying, financing (Mercado Credito) and shipping (Mercado Envios). This stickiness drives a ROE of 26.4%, reflecting pricing power that rivals no pure‑play e‑commerce competitor can replicate without building an equivalent financial stack.
Risk. The price already embeds aggressive expectations— a reverse DCF shows the market assumes a -7% annual free‑cash‑flow growth over the next decade, far below the current 36.4% revenue growth, while the P/E of 47.9 and a debt‑to‑equity of 1.7 signal that any slowdown or margin compression would quickly erode the premium. A sustained dip in growth or a rise in leverage would validate the bear case and crush the upside.
Horizon. 1-3 yr $2,215 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $3,243 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $4,810 if current growth sustains into durable earnings power.
22. FIVE — Five Below, Inc. · score 78.3
Specialty Retail · price $202.63 · 1Y $260.33 · 5Y $381.15 · 10Y $565.42
FCF $505m C+ · Rev +25.9% A- · D/E 0.86 B · P/E 25.6x C+ · PEG 0.98 B+
Why now. Five Below’s explosive 25.9% YoY revenue growth is powered by its ever‑refreshing assortment of teen‑focused novelty gifts, seasonal décor and low‑price fashion accessories, creating a self‑reinforcing compounding loop. The chain converts that top‑line surge into robust $505 m free cash flow and a healthy 19% ROE, while a modest $11.2 b market cap (PE 25.6, PEG 0.98) leaves ample upside. The thesis rests on the persistence of its fast‑turn product cadence that continuously draws price‑sensitive Gen‑Z shoppers.
Moat. The moat lives in Five Below’s ultra‑low‑price, high‑turnover product model – from candy and party supplies to trendy loungewear – that forces shoppers to visit frequently and limits price competition because rivals cannot match its breadth of sub‑$5 SKUs across such a broad assortment. This pricing discipline fuels a 19% ROE, reflecting pricing power in a niche where cost‑efficient sourcing and small‑format stores create a barrier to rapid replication.
Risk. The stock trades at a lofty PE 25.6, already baking in a reverse‑DCF implied 13% annual free‑cash‑flow growth for a decade – well below the current 25.9% revenue expansion, meaning any slowdown would expose a valuation gap. A debt‑to‑equity of 0.86 adds leverage risk, and a beta of 1 makes the share vulnerable to broader market swings; a miss on quarterly growth or margin compression would trigger a sell‑off, confirming the bear case.
Horizon. 1-3 yr $260.33 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $381.15 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $565.42 if current growth sustains into durable earnings power.
23. DECK — Deckers Outdoor Corporation · score 78.2
Footwear & Accessories · price $106.49 · 1Y $127.81 · 5Y $187.13 · 10Y $277.59
FCF $1.1b C+ · Rev +9.8% B · D/E 0.15 A · P/E 15.2x B+ · PEG 1.33 B
Why now. Deckers' HOKA performance‑footwear franchise is fueling a virtuous cycle of top‑line expansion and cash generation – revenue is climbing 9.8% YoY, profit margins sit at a robust 18.7%, and free cash flow tops $1.1 B on a $14.8 B market cap, delivering a 15.2× P/E that still leaves room for upside. The combination of double‑digit growth and a 41% ROE means earnings will keep compounding, and the market’s 127.81 $ consensus target already reflects that trajectory. The thesis rests on HOKA’s continued capture of the premium running and trail segment, which should keep the growth engine humming.
Moat. Deckers locks in pricing power through category leadership in two distinct premium niches – UGG’s high‑margin casual‑luxury footwear and HOKA’s performance‑focused running shoes – giving it a pricing edge that translates into a 41% ROE. Its vertically integrated design‑to‑retail network and exclusive brand distribution through both its own e‑commerce channels and select retailers create switching costs for consumers who value the fit and technology of HOKA and the heritage feel of UGG, a moat competitors can’t replicate quickly.
Risk. The Bull Rankings model flags a modest 4% implied FCF growth over the next decade, far below the current 9.8% revenue growth, meaning the share price already embeds heavy optimism; any slowdown in HOKA’s momentum would compress that gap. At a beta of 1.17 and a PEG of 1.33, the stock trades at a premium to its growth profile, and a miss on quarterly earnings would trigger a sell‑off, confirming the bear case that valuation is stretched.
Horizon. 1-3 yr $127.81 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $187.13 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $277.59 if current growth sustains into durable earnings power.
24. CRDO — Credo Technology Group Holding Ltd · score 77.4
Semiconductors · price $202.68 · 1Y $271.92 · 5Y $398.12 · 10Y $590.58
FCF $407m C · Rev +205.7% A · D/E 0.01 A · P/E 80.4x C · PEG 0.39 A
Why now. Credo’s ZeroFlap (ZF) active electrical cables and ZF optical transceivers are rapidly winning high‑speed Ethernet and PCIe contracts in data‑center and AI‑compute markets, driving a 205.7% YoY revenue surge and a 35.4% profit margin that fuels a PE of 80.4x on a still‑thin share base; the compounding engine is the relentless demand for bandwidth‑intensive workloads, and as long as Credo can keep expanding its ZF portfolio, that growth will persist.
Moat. Credo’s moat stems from its proprietary ZeroFlap cable architecture and SerDes IP licensing, which embed deep technical integration into OEM designs, creating high switching costs for customers that must redesign boards to replace the patented solution; this, combined with a stellar ROE of 22.9%, reflects pricing power derived from being the de‑facto supplier for ultra‑low‑latency Ethernet in hyperscale data centers.
Risk. The stock trades at a lofty PE of 80.4x despite a beta of 3.2, meaning any slowdown in data‑center capex or a successful alternative from rivals could crush the valuation, and the Bull Rankings model flags diluting shareholders as a cautionary signal; a breach of the 52‑week low ($86.48) would confirm the bear case and force a re‑rating.
Horizon. 1-3 yr $271.92 (analyst consensus (n=19)) — fundamentals + valuation re-rating. 5 yr $398.12 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $590.58 if current growth sustains into durable earnings power.
25. NFLX — Netflix, Inc. · score 76.9
Entertainment · price $68.95 · 1Y $111.03 · 5Y $162.56 · 10Y $241.15
FCF $11.2b A- · Rev +16.0% B+ · D/E 0.47 B · P/E 21.7x B · PEG 1.45 B
Why now. Netflix’s global streaming platform is poised to compound earnings by leveraging its ever‑expanding library of original TV series, documentaries, and feature films that keep subscribers glued to its service. The business is growing revenue at 16% YoY, converting that into a rock‑solid 28.2% profit margin and an eye‑popping 45.3% ROE, meaning each dollar of equity is generating nearly half a dollar of profit. The entire thesis rests on the relentless subscription roll‑up in a market where Netflix remains the premier destination for premium, ad‑free content.
Moat. Netflix’s moat is the deep, proprietary content vault it continuously expands, creating a switching cost for members who have invested time in binge‑watching exclusive series. This content advantage fuels pricing power—evidenced by a 45.3% ROE—because the company can command higher subscription fees without losing churn‑sensitive customers. Moreover, its distribution across every internet‑connected device ensures that the content is always within reach, a barrier competitors struggle to replicate quickly.
Risk. The biggest headwind is the lofty valuation: a forward P/E of 21.7 paired with a PEG of 1.45 suggests the market is pricing in growth that may be hard to sustain as competition intensifies and content costs rise. If revenue growth decelerates below the current 16% pace, margins could compress, eroding the 28.2% profit margin and exposing the 0.47 debt‑to‑equity leverage to scrutiny. A breach of the 52‑week high at $126.71 would confirm that the premium is already baked in, and any miss on growth would trigger a sharp re‑rating.
Horizon. 1-3 yr $111.03 (analyst consensus (n=44)) — fundamentals + valuation re-rating. 5 yr $162.56 at ~19% CAGR — compounding case rests on the competitive position widening. 10 yr $241.15 if current growth sustains into durable earnings power.
26. YUMC — Yum China Holdings, Inc. · score 76.4
Restaurants · price $43.87 · 1Y $61.34 · 5Y $89.81 · 10Y $133.23
FCF $931m C+ · Rev +6.7% C+ · D/E 0.38 A- · P/E 16.8x B+ · PEG 1.08 B+
Why now. Yum China’s KFC and Pizza Hut franchise network is still expanding in the world’s largest fast‑food market, delivering 6.7% revenue growth YoY while generating $931 m of free cash flow and trading at a modest PE of 16.8, which together give a clear path to compounding earnings as Chinese dining out continues to rise.
Moat. The company’s franchised KFC and Pizza Hut concepts lock in recurring royalties and supply‑chain efficiencies, creating a cost advantage that fuels a ROE of 17.4%—far above the sector average and hard for new entrants to replicate quickly.
Risk. A slowdown in Chinese consumer spending could erode the modest 7.8% profit margin and the 6.7% growth rate, while the stock’s valuation at a PE of 16.8 already embeds optimism; a sustained margin contraction or growth deceleration would trigger a sell‑off and invalidate the growth thesis.
Horizon. 1-3 yr $61.34 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $89.81 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $133.23 if current growth sustains into durable earnings power.
27. FISV — Fiserv, Inc. · score 75.9
Sector n/a · price $50.63 · 1Y $67.37 · 5Y $85.05 · 10Y $109.08
FCF $4.1b B · Rev +9.3% B · D/E n/a · P/E 8.6x A- · PEG 2.38 C
Why now. Sector n/a · market cap $27.0b. Down 70% from 52-week high of $168.02 — deep drawdown territory. 27 sell-side analysts rate this a Hold with a mean 1-yr target of $67.37 (implying +33% upside).
Moat. Net margin 20% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 12% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 129% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 70% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $67.37 (analyst consensus (n=27)) — multiple re-rating thesis requires a catalyst. 5 yr $85.05 at ~11% CAGR — dividend + buyback compounding. 10 yr $109.08 if the moat survives secular pressure.
28. EME — EMCOR Group, Inc. · score 75.6
Engineering & Construction · price $744.16 · 1Y $1,000 · 5Y $1,263 · 10Y $1,619
FCF $1.1b C+ · Rev +18.3% B+ · D/E 0.13 A · P/E 25.0x B+ · PEG 0.41 A
Why now. Engineering & Construction · market cap $33.1b. Down 22% from 52-week high of $951.96 — deep drawdown territory. Revenue growing +18%, comfortably above the S&P median. PEG 0.41 — paying under fair value for the growth rate. 7 sell-side analysts rate this a Buy with a mean 1-yr target of $1,000 (implying +34% upside).
Moat. ROE 35% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $1,000 (analyst consensus (n=7)) — multiple re-rating thesis requires a catalyst. 5 yr $1,263 at ~11% CAGR — dividend + buyback compounding. 10 yr $1,619 if the moat survives secular pressure.
29. ULTA — Ulta Beauty, Inc. · score 75.5
Specialty Retail · price $479.57 · 1Y $623.58 · 5Y $912.99 · 10Y $1,354
FCF $1.1b C+ · Rev +11.3% B · D/E 0.89 B · P/E 18.0x B+ · PEG 1.63 C+
Why now. Specialty Retail · market cap $20.6b. Down 33% from 52-week high of $714.97 — deep drawdown territory. Revenue growing +11%, comfortably above the S&P median. 24 sell-side analysts rate this a Buy with a mean 1-yr target of $623.58 (implying +30% upside).
Moat. ROE 46% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 95% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 33% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $623.58 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $912.99 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $1,354 if current growth sustains into durable earnings power.
30. DEO — Diageo plc · score 74.1
Beverages - Wineries & Distilleries · price $84.00 · 1Y $101.14 · 5Y $148.08 · 10Y $219.67
FCF n/a · Rev +4.8% C+ · D/E 1.77 C · P/E 19.4x B · PEG 0.79 A-
Why now. Beverages - Wineries & Distilleries · market cap $46.7b. Down 28% from 52-week high of $116.41 — deep drawdown territory. PEG 0.79 — paying under fair value for the growth rate. 7 sell-side analysts rate this a Buy with a mean 1-yr target of $101.14 (implying +20% upside).
Moat. Net margin 16% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 41% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which.
Risk. Dividend payout 96% of earnings on a 4.0% yield — distribution coverage is thin; one earnings stumble could force a dividend cut.
Horizon. 1-3 yr $101.14 (analyst consensus (n=7)) — fundamentals + valuation re-rating. 5 yr $148.08 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $219.67 if current growth sustains into durable earnings power.
Methodology footnote
Every pick on this list comes out of the same quality-growth model — one 0–100 score blending quality, growth, and value — applied to every US-listed common stock with a market cap above $1B. Each pick's score breakdown is auditable from the home page — click the ticker on the rankings page to see exactly which grades produced the number. Not investment advice. See terms for full disclosures.